Connection

WEIYA XIA to Animals

This is a "connection" page, showing publications WEIYA XIA has written about Animals.
Connection Strength

0.272
  1. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022 10; 3(10):1211-1227.
    View in: PubMed
    Score: 0.009
  2. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. J Biol Chem. 2022 04; 298(4):101817.
    View in: PubMed
    Score: 0.009
  3. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat Commun. 2021 12 06; 12(1):7041.
    View in: PubMed
    Score: 0.009
  4. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nat Commun. 2021 05 13; 12(1):2788.
    View in: PubMed
    Score: 0.008
  5. Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma. J Exp Clin Cancer Res. 2020 Dec 05; 39(1):273.
    View in: PubMed
    Score: 0.008
  6. Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma. J Hepatol. 2021 04; 74(4):907-918.
    View in: PubMed
    Score: 0.008
  7. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020 10; 22(10):1264-1275.
    View in: PubMed
    Score: 0.008
  8. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2019 11 08; 10(1):5114.
    View in: PubMed
    Score: 0.007
  9. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019 07 15; 129(8):3324-3338.
    View in: PubMed
    Score: 0.007
  10. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019 07; 20(7):835-851.
    View in: PubMed
    Score: 0.007
  11. PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. Nat Commun. 2019 02 07; 10(1):636.
    View in: PubMed
    Score: 0.007
  12. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. 2019 05; 156(6):1849-1861.e13.
    View in: PubMed
    Score: 0.007
  13. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 2019 01; 29(1):83-86.
    View in: PubMed
    Score: 0.007
  14. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018 08 16; 71(4):606-620.e7.
    View in: PubMed
    Score: 0.007
  15. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018 08; 28(8):862-864.
    View in: PubMed
    Score: 0.007
  16. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression. Cancer Res. 2018 07 15; 78(14):3761-3768.
    View in: PubMed
    Score: 0.007
  17. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018 05 15; 9(1):1908.
    View in: PubMed
    Score: 0.007
  18. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell. 2018 04 09; 33(4):752-769.e8.
    View in: PubMed
    Score: 0.007
  19. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018 02 12; 33(2):187-201.e10.
    View in: PubMed
    Score: 0.007
  20. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017 12 01; 127(12):4498-4515.
    View in: PubMed
    Score: 0.007
  21. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017 Jul 15; 23(14):3711-3720.
    View in: PubMed
    Score: 0.006
  22. A UBE2O-AMPKa2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy. Cancer Cell. 2017 02 13; 31(2):208-224.
    View in: PubMed
    Score: 0.006
  23. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016 Dec 12; 30(6):925-939.
    View in: PubMed
    Score: 0.006
  24. Aurora A kinase activates YAP signaling in triple-negative breast cancer. Oncogene. 2017 03 02; 36(9):1265-1275.
    View in: PubMed
    Score: 0.006
  25. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632.
    View in: PubMed
    Score: 0.006
  26. AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res. 2016 Mar 15; 76(6):1451-62.
    View in: PubMed
    Score: 0.006
  27. EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Res. 2016 Mar 01; 76(5):1284-96.
    View in: PubMed
    Score: 0.006
  28. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Sci Signal. 2014 Jul 29; 7(336):ra71.
    View in: PubMed
    Score: 0.005
  29. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res. 2013 Nov 01; 73(21):6516-25.
    View in: PubMed
    Score: 0.005
  30. Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLoS One. 2013; 8(9):e73406.
    View in: PubMed
    Score: 0.005
  31. Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers. Cancer Cell. 2013 Jun 10; 23(6):796-810.
    View in: PubMed
    Score: 0.005
  32. SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. Genes Dev. 2013 Feb 01; 27(3):274-87.
    View in: PubMed
    Score: 0.005
  33. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 2012 Mar 20; 21(3):374-87.
    View in: PubMed
    Score: 0.004
  34. Epithelial-mesenchymal transition induced by TNF-a requires NF-?B-mediated transcriptional upregulation of Twist1. Cancer Res. 2012 Mar 01; 72(5):1290-300.
    View in: PubMed
    Score: 0.004
  35. IKKa activation of NOTCH links tumorigenesis via FOXA2 suppression. Mol Cell. 2012 Jan 27; 45(2):171-84.
    View in: PubMed
    Score: 0.004
  36. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest. 2011 Nov; 121(11):4526-36.
    View in: PubMed
    Score: 0.004
  37. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Mol Cancer Ther. 2011 Aug; 10(8):1327-36.
    View in: PubMed
    Score: 0.004
  38. Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. Cancer Res. 2010 Oct 01; 70(19):7684-9.
    View in: PubMed
    Score: 0.004
  39. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther. 2009 Aug; 8(8):2375-82.
    View in: PubMed
    Score: 0.004
  40. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. Cancer Gene Ther. 2004 Sep; 11(9):594-602.
    View in: PubMed
    Score: 0.003
  41. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001 Nov; 3(11):973-82.
    View in: PubMed
    Score: 0.002
  42. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001 Sep; 3(9):802-8.
    View in: PubMed
    Score: 0.002
  43. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001 Mar; 3(3):245-52.
    View in: PubMed
    Score: 0.002
  44. The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice. Cancer Res. 2000 Sep 01; 60(17):4913-20.
    View in: PubMed
    Score: 0.002
  45. Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. Cancer Res. 2000 Jun 15; 60(12):3123-6.
    View in: PubMed
    Score: 0.002
  46. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem. 2000 Mar 17; 275(11):8027-31.
    View in: PubMed
    Score: 0.002
  47. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med. 2000 Feb; 6(2):189-95.
    View in: PubMed
    Score: 0.002
  48. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res. 1999 Feb; 5(2):343-53.
    View in: PubMed
    Score: 0.002
  49. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene. 1998 Oct 29; 17(17):2167-75.
    View in: PubMed
    Score: 0.002
  50. Safety studies of the intraperitoneal injection of E1A--liposome complex in mice. Gene Ther. 1997 Mar; 4(3):238-43.
    View in: PubMed
    Score: 0.002
  51. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene. 1997 Feb 06; 14(5):561-8.
    View in: PubMed
    Score: 0.002
  52. Inhibition of intratracheal lung cancer development by systemic delivery of E1A. Oncogene. 1996 Oct 03; 13(7):1405-12.
    View in: PubMed
    Score: 0.002
  53. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene. 1995 Oct 05; 11(7):1383-8.
    View in: PubMed
    Score: 0.001
  54. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene. 1995 May 18; 10(10):1947-54.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.